Business Wire

Retina Implant AG Founder Professor Eberhart Zrenner and Research Team Honoured at EURETINA

Share
RETINA-IMPLANT-AG

EURETINA Presents the First Ever Innovation Award for Zrenner’s Subretinal Research Work

Retina Implant AG today announced that the Company’s founder Professor Eberhart Zrenner M.D. was awarded the second prize by The European Society for Retina Specialists (EURETINA). Professor Zrenner received the group’s inaugural Innovation Awards in London last week for his work in the field of artificial vision.

Dr. Zrenner, professor of Ophthalmology and director Emeritus of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the University of Tuebingen and the project team consisting of research teams from several universities, received the award for their investigations into subretinal implant technology.

Speaking of the award, Dr. Zrenner said: ‘It is an incredible honour that such a prestigious community of my peers has presented me with this award. We are proud of the work our team has done to restore useful vision to those suffering from retinitis pigmentosa.”

In 2003, Professor Zrenner and the leading project team managers founded Retina Implant AG , a leading developer of subretinal implants for the visually impaired. Zrenner and the team designed a 3 x 3 mm2 array containing 1,500 electrodes to stimulate the damaged cells using pulsed, light-dependent electrical stimuli. The team’s goal was to restore useful vision to the blind in order to provide these patients with some independence and to date clinical trials have produced positive results.

Retina Implant AG’s first clinical trial began in 2005 at the University Eye Clinic of Tuebingen, Germany by implanting 11 patients. Results of the first clinical trial have been presented at several industry-wide scientific meetings and were published in the journal Proceedings of the Royal Society B last November.

The 2011 EURETINA Innovation Award is a new initiative sponsored by EURETINA to support and encourage innovation in the field of retinal medicine. These awards aim to facilitate and support an entrepreneurial culture to deliver new market applications for the ultimate benefit of patients with retinal disorders, as well as engage and encourage the networking potential of the retinal community across the EU to improve both patient care and outcomes.

There were over 20 applications for the award and six finalists. As part of the short-listing process, nominees were invited to present their innovation at the EURETINA Congress. The winner was then selected by a judging panel chaired by Prof. Einar Stefansson of Landspitali University Hospital. The other finalists included Dr J Farrar (Trinity College) research into mutation-independent gene therapy for rhodo-spin linked autosomal dominant retinitis pigmentosa and Dr M Rudolf (University of Luebeck) and his team’s development of novel drug candidates for the prevention and treatment of age-related macular degeneration, which won the first prize.

###

Notes to Editor:

Photos available upon request

About Retina Implant AG

Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with private investors with the goal of developing the first fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005, and has started a second clinical trial this year. To learn more, visit: http://www.retina-implant.de/ .

About Professor Zrenner

Dr Zrenner is Professor of Ophthalmology and Director Emeritus of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the University of Tuebingen, Germany. His research interests include: retinal physiology and pathophysiology, neuroophthalmology, retina implants, electrophysiology and other methods of non-invasive function testing, neurodegeneration and ophthalmogenetics.

Dr Zrenner studied electronic engineering as well as medicine at the Technical University Munich, where he obtained his MD degree in 1972. Subsequently he worked within the Max-Planck-Society for 16 years and received a Fogarty fellowship at the national Eye Institute, Bethesda, MD (1977 and 1978), studying temporal, spatial and chromatic characteristics of retinal ganglion cells via extracellular recordings in monkey retina. After acquiring a Privatdozent (PD) degree he received an associated professorship at the University Eye Hospital in Munich. He became full professor and Medical Director of the University Eye Hospital in Tuebingen in 1989, now Center for Ophthalmology; he also served twice as Dean of the Medical Faculty of Tuebingen and also as Visiting Professor at the State University New York N.Y. USA.

Contact:

Schwartz Communications
Charlotte Webber / Amanda Hayhurst
+44 (0)208 090 4796
Retinaimplant@schwartzcomm.com
or
Retina Implant AG
Dr. Walter-G. Wrobel
+ 49 7121 | 36403-111
Walter.Wrobel@retina-implant.de

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 12:45:00 CEST | Press release

Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Pra

Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 15:57:00 CEST | Press release

The Time-Series Transformer AI FX Model forecasts cashflow and FX exposure with more than 90% accuracy, helping businesses reduce FX-related fees Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model

IFF Completes Divestiture of Nitrocellulose Business9.5.2025 14:00:00 CEST | Press release

IFF (NYSE: IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF’s Pharma Solutions business unit. “The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses,” said Erik Fyrwald, IFF CEO. “I’d like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Le

Monument Re Transfers €1.4bn Greycastle Portfolio to RGA and Strengthens European Life Insurance Consolidation Platform9.5.2025 14:00:00 CEST | Press release

Monument Re Limited (“Monument”) announces today that it has transferred a legacy €1.4bn reinsurance portfolio, comprising annuity and other life insurance liabilities acquired as part of the 2020 Greycastle transaction, to RGA Americas Reinsurance Company, Ltd. (“RGA”). This transaction releases capital resources that Monument will redirect to its core strategy of consolidation in European life insurance markets. The transaction completed on 2May 2025 following approval by the Boards of Directors of both Monument and RGA and non-objection from the Bermuda Monetary Authority. Monument has taken significant steps in recent months to strengthen its business operations by consolidating its European group support functions in Dublin and by aligning with the recently strengthened regulatory regime in Bermuda. With its strong financial position and best in class capabilities in the Group, Monument remains ideally positioned to build on its success to date and grow its European footprint, del

CPAC Systems AB Announces Strategic Minority Investment in Flying Fish9.5.2025 12:33:00 CEST | Press release

Accelerating the shift toward sustainable and intelligent water mobility CPAC Systems AB, a leader in advanced control systems and embedded vessel and commercial vehicle technology, today announced a strategic minority investment in Flying Fish Maritime Innovations B.V., a pioneer in advanced shared water mobility solutions and robust, cost-effective hydrofoil technology. The investment underscores both companies’ commitment to redefining water-based transportation through innovation, sustainability, and seamless integration. It marks the beginning of a deeper collaboration aimed at enabling smarter, cleaner, and more connected mobility on the water — for both recreational and commercial applications. “We are thrilled to support Flying Fish and their impressive work in redefining water mobility,"saidMarcus Wingolf, CEO of CPAC Systems. "Our investment in Flying Fish represents a strategic alignment of our technical proficiencies and innovative ambitions. This partnership opens exciting

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye